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The deﬁ nition of cryptogenic stroke or stroke of 
undetermined origin is aﬀ ected by the current knowledge 
of the cause and pathogenesis of stroke and by the 
availability, comprehensiveness, quality, and timeliness 
of the ancillary investigations undertaken to discover 
the cause of the stroke.1 In The Lancet Neurology, Linxin Li 
and colleagues2 report ﬁ ndings from a population-based 
study of the burden, outcome, risk factors, and long-term 
prognosis of cryptogenic stroke in patients with a ﬁ rst 
transient ischaemic attack (TIA) or ischaemic stroke. They 
found that of 2555 ﬁ rst ischaemic events, 812 (32%) 
were cryptogenic. The study shows that the prognosis of 
cryptogenic stroke and the risk of recurrence are similar to 
those of large artery disease and small vessel disease. For 
example, death or dependency at 6 months was similar 
after cryptogenic stroke compared with large artery and 
small vessel subtypes combined (23% vs 27%; p=0·26), 
as was the 10-year risk of recurrence (32% vs 27%; 
p=0·91). Secondary stroke prevention must be similarly 
aggressive and appropriate in stroke with and without 
identiﬁ ed cause. The ﬁ ndings from this Article question 
the role of paroxysmal atrial ﬁ brillation as the major 
cause of cryptogenic stroke, which contrasts with the 
present enthusiasm for the use of technology to detect 
paroxysmal atrial ﬁ brillation3 and for the possibility to 
prevent recurrent cryptogenic stroke with anticoagulants.
The results of this study are especially important 
for health-care policy makers, because they show 
the burden of cryptogenic stroke, the rationale for 
a comprehensive investigation into the cause of 
every ischaemic stroke, and the need to provide 
stroke centres with access to the necessary ancillary 
diagnostic procedures. The diagnostic work up used in 
this study is unfortunately still not routinely used for 
every patient with ischaemic stroke, neither in the UK 
nor in mainland Europe. In developing countries, such 
diagnostic instruments are a distant mirage. 
This study has some limitations that hamper the 
translation of its results into routine practice: both TIAs 
and strokes were included, and the diagnosis of TIA 
can be erroneous even when done by a specialist; the 
causative investigation was incomplete, especially in 
phase 1; the search for paroxysmal atrial ﬁ brillation was 
not pursued intensively; the investigation of the cause 
of stroke in recurrent strokes was incomplete; and the 
newest devices for prolonged heart rhythm monitoring 
were not used. All these limitations might have resulted 
in misclassiﬁ cation of some strokes as cryptogenic and 
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dose and location, augmentation of treatment eﬀ ects, 
expansion of applicability, and cost-eﬀ ectiveness should 
be addressed in future research.
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See Review page 926 Alzheimer’s disease is devastating for the individual, 
family, and society. Prevention of this disease, or halting 
it in the early stages of progression, is imperative. 
Prevention of Alzheimer’s disease will have to 
encompass two new paradigms: ﬁ rst, that the syndrome 
is not a single disease caused by one pathway; and 
second, that the disease starts much earlier than its 
clinical symptoms. The present challenge is to identify 
susceptible asymptomatic subgroups in the population 
and apply biological, behavioural, and ﬁ nancially 
decrease the probability of detecting atrial ﬁ brillation and 
of classifying a stroke as cardioembolic during follow-up.
Other aspects in the investigation of cryptogenic stroke 
are diﬃ  cult to enforce in population-based studies. 
Examples include emergent echocardiography so as 
not to miss intracardiac thrombus; early imaging of the 
neck vessels, including cervical MRI with fat suppression, 
to detect arterial dissection; and transoesophageal 
echocardiogram to exclude patent foramen ovale in all 
age groups4 and to rule out prominent or complicated 
atheroma in elderly patients. Patients with evidence 
of right-to-left shunt but no patent foramen ovale 
should be assessed for pulmonary ﬁ stulae. In middle 
aged and elderly patients with no cause for their stroke, 
searching for an occult neoplasm should be considered. 
In a systematic review and meta-analysis,5 a four-phase 
sequential search for paroxysmal atrial ﬁ brillation—using 
(1) electrocardiogram (ECG); (2) serial ECG, in-hospital 
continuous monitoring, and Holter; (3) ambulatory 
Holter; and (4) mobile cardiac telemetry and external and 
implantable loop recorders—increased the percentage of 
detected atrial ﬁ brillation from 8% after an admission 
ECG only to an overall detection yield of 24%. 
Nevertheless, the messages from the present Article 
for the practising neurologist are clear: (1) do not be 
surprised to ﬁ nd no cause in a third of ischaemic strokes; 
(2) do not label a patient as having a cryptogenic stroke 
before completion of a comprehensive investigation of 
possible causes; (3) educate the patient on risk-factor 
control and prescribe an antihypertensive, a statin, and 
an antiplatelet drug to prevent recurrence; and (4) do 
not expect that detection of paroxysmal atrial ﬁ brillation 
and anticoagulation will solve the mystery of cryptogenic 
stroke and eliminate stroke recurrence in these patients. 
The aim of future research on this topic should be 
to decrease the proportion of strokes classiﬁ ed as 
cryptogenic and to prevent vascular recurrences in 
patients with these strokes. Technological priorities 
in research include user-friendly devices to detect 
atrial ﬁ brillation, cardiac MRI to depict structural and 
functional abnormalities associated with increased 
stroke risk, and high-resolution MRI of intracranial 
vessels to visualise strategic or unstable atheroma. 
Multicentre collaborative studies will be necessary to 
identify biomarkers of new genetic, inﬂ ammatory, 
infectious, and oncological disorders associated 
with stroke (eg, NCT01934725). Results of ongoing 
trials with novel oral anticoagulants in patients with 
embolic strokes of unknown origin6 will be available in 
a few years (NCT02313909, NCT02239120). Even if the 
results of these trials are negative, anticoagulation will 
still be indicated in all patients with cryptogenic stroke 
if de-novo atrial ﬁ brillation is detected. Psychosocial 
outcomes and their determinants (eg, insecurity for 
having no cause for their stroke or fear of recurrence) 
also need to be investigated in these patients with 
stroke in whom no cause is discovered.
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